GMSO.1

Generic Name:
GMSO.1
Therapeutic Category:
Oral Anti-Diabetic Combination (Sulfonylurea + Biguanide)
Mechanism of Action:
Dual-action glycemic control. Glimepiride stimulates insulin secretion from pancreatic beta cells, while Metformin decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.

Indications

Dosage & Administration

Contraindications & Precautions

Potential Side Effects

Indications (Therapeutic Uses)

This combination tablet is indicated for the management of type 2 diabetes mellitus when dietary modification, physical exercise, and monotherapy do not result in adequate glycemic control:

  • Type 2 Diabetes Mellitus: Long-term management to improve glycemic control in adult patients.
  • Secondary Monotherapy Failure: For patients whose blood glucose levels are no longer adequately managed by metformin or a sulfonylurea alone.
  • Therapy Stabilization: To replace separate tablets of metformin and glimepiride given concurrently for ease of compliance.

Dosage & Administration

Website Note: Dosage must be individualized by a registered medical practitioner based on the patient’s current treatment regimen, effectiveness, and tolerance.

  • Standard Dose: Initially one tablet taken orally once daily. The dosage can be gradually titrated based on blood glucose monitoring.
  • Administration: Tablets must be swallowed whole with water. Do not crush, break, or chew sustained-release tablets, as doing so releases the entire dose at once, increasing side effect risks.
  • Timing: Must be taken with meals (typically with breakfast or the first main meal of the day) to minimize gastrointestinal side effects and reduce the risk of hypoglycemia.

Contraindications & Precautions

  • Absolute Contraindications: Do not use in patients with known hypersensitivity to glimepiride, metformin, or other sulfonylureas/biguanides. Strictly contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal impairment (e.g., eGFR less than 30 mL/min), or acute/chronic metabolic acidosis.
  • Lactic Acidosis Warning: Metformin carries a rare but serious risk of lactic acidosis, a potentially fatal metabolic complication characterized by elevated blood lactate levels. The risk increases with conditions like renal insufficiency, sepsis, dehydration, and excessive alcohol intake.
  • Hypoglycemia Risk: Glimepiride can cause severe hypoglycemia (low blood sugar). Patients should be educated on recognizing symptoms (sweating, tremors, palpitations) and managing them with fast-acting carbohydrates.
  • Iodinated Contrast Media: Discontinue this medication temporarily at the time of, or prior to, iodinated contrast imaging procedures in patients with an eGFR between 30 and 60 mL/min, or a history of liver disease, alcoholism, or heart failure. Re-evaluate 48 hours post-procedure.

Potential Side Effects

  • Common / Mild: Hypoglycemia, gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain, flatulence, metallic taste), headache, and dizziness. Gastrointestinal symptoms are common during initial therapy and usually resolve spontaneously.
  • Less Common / Severe: Lactic acidosis, severe prolonged hypoglycemia, dermatological allergic reactions (pruritus, erythema, urticaria), hematological changes (leukopenia, thrombocytopenia), and impaired Vitamin B-12 absorption (with long-term metformin use).
Soins Heaalthcare Logo

Designed & Developed By The Brand Projects

Linkedin-in